IPCALAB IPCA Laboratories Q1 FY26 results (Apr–Jun 2025) and concall
Ipca Labs reported a mixed Q1 FY26 with strong standalone and consolidated net profit growth, driven by robust domestic and export performance. However, consolidated EBITDA margins saw a slight decline, primarily due to underperformance and one-time provisions within the Unichem subsidiary. The company revised its full-year consolidated EBITDA margin improvement guidance downwards, while maintaining topline growth targets.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 2,355 | 2,245 | 2,247 | 2,309 |
| EBITDA | 441 | 463 | 429 | 416 |
| Net profit | 246 | 276 | 64 | 233 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
